Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:19 PM
Ignite Modification Date:
2025-12-24 @ 1:19 PM
NCT ID:
NCT00661895
Eligibility Criteria:
Inclusion Criteria:
1. Demographics: men or women of self-declared African-American heritage between 25 and 80 years of age residing in the Omaha, Nebraska metropolitan area
2. History of documented uncontrolled (treated or untreated) hypertension (HTN) as defined by JNC 7 guidelines
3. Study eligibility will be based on the subject's current blood pressure control based on the average of two seated blood pressure measurements at two consecutive clinic visits at least one week apart
1. Untreated subjects with elevated blood pressure (\> 140/90 mmHg or \< 130/80 mmHg for diabetics)
2. Subjects treated with antihypertensive therapy whose blood pressure does not meet current JNC 7 guidelines (\< 140/90 mmHg for non-diabetics and \< 130/80 mmHg for diabetics)
Exclusion Criteria:
1. Myocardial infarction or stroke in the previous 6 months
2. Symptomatic heart failure or a left ventricular ejection fraction \< 35%
3. Angina pectoris in the prior six months
4. Coronary revascularization procedure in the prior 6 months
5. Renal insufficiency defined as a serum creatinine \> 2 mg/dl
6. Illicit drug or alcohol abuse in the prior 6 months
7. Dementia or other organic brain disease
8. Serious systemic illness with a shortened life expectancy or other limitation that precludes participation in this trial
9. Secondary HTN
10. Concurrent participation in an investigational medication trial
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
25 Years
Maximum Age:
80 Years
Study:
NCT00661895
Study Brief:
Protocol Section:
NCT00661895